PDF(Pubmed)
Abstract：
Durvalumab after chemotherapy in non-operable stage III non-small cell lung cancer (NSCLC) is the standard of care worldwide. We present a patient with the incidental discovery of a unilateral MALT lymphoma of the adrenal gland and adrenalitis during durvalumab maintenance treatment detected by 18F-FDG-PET/CT. We assessed the clinical and histopathological findings, radiological examinations and overall treatment. Our work emphasizes the significance of considering other differential diagnoses and the importance of multidisciplinary treatment of the findings, especially within clinical trials.
摘要：
Durvalumab在不可手术的III期非小细胞肺癌（NSCLC）化疗后是世界范围内的治疗标准。我们介绍了在18F-FDG-PET/CT检测到的durvalumab维持治疗期间偶然发现的肾上腺单侧MALT淋巴瘤和肾上腺炎的患者。我们评估了临床和组织病理学发现，放射学检查和整体治疗。我们的工作强调了考虑其他鉴别诊断的重要性以及对发现进行多学科治疗的重要性。尤其是在临床试验中。
